Market capitalization | $133.62b |
Enterprise Value | $142.55b |
P/E (TTM) P/E ratio | 74.99 |
EV/FCF (TTM) EV/FCF | 66.12 |
EV/Sales (TTM) EV/Sales | 8.96 |
P/S ratio (TTM) P/S ratio | 8.40 |
P/B ratio (TTM) P/B ratio | 6.45 |
Revenue growth (TTM) Revenue growth | 15.65% |
Revenue (TTM) Revenue | $15.91b |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
36 Analysts have issued a Boston Scientific forecast:
36 Analysts have issued a Boston Scientific forecast:
Sep '24 |
+/-
%
|
||
Revenue | 15,910 15,910 |
16%
16%
|
|
Gross Profit | 9,929 9,929 |
17%
17%
|
|
EBITDA | 3,858 3,858 |
19%
19%
|
EBIT (Operating Income) EBIT | 2,623 2,623 |
27%
27%
|
Net Profit | 1,791 1,791 |
46%
46%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.
Head office | United States |
CEO | Michael Mahoney |
Employees | 48,000 |
Founded | 1979 |
Website | www.bostonscientific.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.